Crinetics Pharmaceuticals to Participate in December Investor Conferences

Rhea-AI Summary

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced its participation in key conferences in December 2020. Management will present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3rd, showcasing their innovations in oral drugs. Additionally, they will also feature in the Piper Sandler's 32nd Annual Healthcare Conference from December 1st to 3rd, with on-demand presentations available. The company focuses on developing novel therapeutics for rare endocrine diseases, with its lead candidate, paltusotine, targeting acromegaly and other conditions.

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that company management will participate in the following conferences in the month of December. Please see additional details below:  

Evercore ISI 3rd Annual HealthCONx Conference
Date:		Thursday, December 3rd, 2020
Time:		1:00 - 1:45 pm ET in Track 1
Panel:		Easy Pills to Swallow: Oral Drugs for Large Endo Markets
Presenter:		Dr. Scott Struthers, Founder & CEO
Piper Sandler's 32nd Annual Healthcare Conference
Date:		Tuesday - Thursday, December 1st - 3rd, 2020
Time:		On demand
Presenter:		Dr. Scott Struthers, Founder & CEO, and Dr. Alan Krasner, Chief Medical Officer
Webcast:		Pre-recorded fireside chats are available for the annual Piper Sandler Healthcare Conference on the Events section on the Company’s website as well as on the Piper Sandler conference website.

About Crinetics Pharmaceuticals 
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, paltusotine (formerly CRN00808), is an oral selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 program in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing CRN04777, an oral nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing’s disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company’s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company. For more information, please visit https://crinetics.com.

Contacts:
Marc Wilson
Chief Financial Officer
IR@crinetics.com
(858) 450-6464

Investors / Media:
Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com
(212) 915-2577

Aline Sherwood
Scienta Communications
asherwood@scientapr.com
(312) 238-8957

FAQ

What is the purpose of Crinetics Pharmaceuticals' participation in the December 2020 conferences?

Crinetics Pharmaceuticals aims to showcase their advancements in oral drug therapies and discuss innovations in treating rare endocrine diseases.

When is Crinetics Pharmaceuticals presenting at the Evercore ISI 3rd Annual HealthCONx Conference?

Crinetics Pharmaceuticals will present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3rd, 2020.

Who is presenting for Crinetics Pharmaceuticals at the upcoming conferences?

Dr. Scott Struthers, Founder and CEO, will present at both conferences, alongside Dr. Alan Krasner, Chief Medical Officer during the Piper Sandler's conference.

What is the lead product candidate of Crinetics Pharmaceuticals and its intended use?

The lead product candidate is paltusotine, designed for treating acromegaly, a rare endocrine disease.

What is the timeline for Crinetics Pharmaceuticals' paltusotine development?

Crinetics Pharmaceuticals plans to advance paltusotine into a Phase 3 program in acromegaly and a Phase 2 trial for carcinoid syndrome in 2021.